Source-checked summary of NexLife’s published pricing, named pharmacy partners, fees, and disclosures, confirmed against its live site. NexLife is not the lowest advertised price in every comparison; this page shows where it’s competitive and where it isn’t.
As of 2026-06-25, GLP-1 Review Board has not established a referral relationship with NexLife. If one is established it will be disclosed here and logged in the update history. See our affiliate disclosure. Compensation, if any, would not affect this review or NexLife’s position in any list.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Medication | Monthly | Prepaid effective | Provenance |
|---|---|---|---|
| Compounded tirzepatide | $215 | $195 (3mo) · $190 (6mo) · $186 (12mo) | provider-published |
| Compounded semaglutide | $165 | $149 (3mo) · $147 (6mo) · $145 (12mo) | confirmed on live page 2026-06-25 |
Semaglutide ladder ($165 / $149 / $147 / $145) confirmed on NexLife’s live semaglutide page on 2026-06-25. Tirzepatide pages list both $215 (month-to-month) and ~$186 (12-month effective).
• Membership: none advertised (confirmed on live page).
• Shipping: free (confirmed on live page).
• Dose-increase: "same price at every dose" advertised (confirmed); not audited across doses.
• Bundled (provider-stated value): nutrition plan, a 1:1 fitness call, and provider review are listed as included ("$377 in added value"). This is NexLife’s own valuation, not an independent one.
• Payment: Klarna / Afterpay shown at checkout (confirmed).
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
NexLife’s safety disclosures name specific potential pharmacy partners — Absolute, Hallandale, Red Rock, Empower, and Strive among 503A pharmacies, plus unnamed FDA-registered 503B outsourcing facilities — and references USP <797> sterile-compounding standards and possible methylcobalamin (B12) in some formulations (confirmed on live page 2026-06-25). This is partial transparency: it discloses a set of possible fillers and the standards they operate under, but does not tell you the specific pharmacy that will fill a given order, and accreditation is described as applying "where applicable" rather than confirmed per partner. That is more disclosure than providers who name no pharmacy, and less than a provider that names the exact 503A and 503B per program. See the pharmacy transparency comparison.
NexLife states it serves eligible patients in U.S. states "where affiliated providers are licensed and pharmacy fulfillment is legally permitted" (provider-stated; not independently verified state by state). Note this is a conditional availability statement, not a confirmed "licensed in all 50 states" claim.
Availability may vary by state and prescribing basis; not independently confirmed state by state. Verify directly before enrolling.
• Cancellation: subscription cancelable (provider-stated). Read the Terms of Service.
• Money-back warranty: "follow the plan, lose up to 10% in 6 months or get your money back," subject to Terms (provider-stated). Confirm the exact conditions before relying on it.
• "Currently the most effective on the market." Marketing superlative in NexLife’s "Verdict" copy; not independently verified and not something we repeat as fact.
• "15% / 24.3% weight loss." These are results from trials of the FDA-approved branded products (semaglutide / tirzepatide), not of NexLife’s compounded formulation. The page borrows them.
• Member outcome stats (29 lbs avg, 98%, 91% recommend). Self-reported, member-collected data labeled as such on the page — not a controlled study.
• Press logos / "ranked" badges / Trustpilot 4.1. "Featured in" mentions and third-party aggregator badges, not endorsements of NexLife’s clinical quality.
• Strong, accurate disclosures (credit where due): the page states plainly that compounded medications are not FDA-approved, that compounded semaglutide is not Ozempic/Wegovy and compounded tirzepatide is not Mounjaro/Zepbound, that NexLife is not affiliated with Novo Nordisk or Eli Lilly, and that outcomes are not guaranteed. That is better disclosure than many competitors.
Confirmed 2026-06-25: semaglutide $165/mo, ~$145 on a 12-month plan; tirzepatide $215/mo, ~$186 on 12 months. Compounded GLP-1 is not FDA-approved.
Its disclosures name potential 503A partners including Absolute, Hallandale, Red Rock, Empower, and Strive, plus unnamed 503B outsourcing facilities, operating under USP <797>. It does not specify which pharmacy fills a given order, so this is partial transparency.
NexLife states it serves patients where its affiliated providers are licensed and fulfillment is permitted — a conditional statement, not a confirmed 'licensed in all 50 states' claim. We have not independently verified state-by-state availability.
No. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound — which NexLife's own page states.
Update history. 2026-06-25 — updated from NexLife’s live pricing and safety-disclosure pages: semaglutide ladder confirmed, named pharmacy partners and USP <797> added, marketing claims (outcome stats, 'most effective,' borrowed trial figures) flagged, strong FDA disclosures credited. No referral relationship at publication.